Atticus Wealth Management LLC Acquires 2,292 Shares of Pfizer Inc. (NYSE:PFE)

Atticus Wealth Management LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFEGet Rating) by 40.4% during the second quarter, HoldingsChannel reports. The institutional investor owned 7,968 shares of the biopharmaceutical company’s stock after buying an additional 2,292 shares during the period. Atticus Wealth Management LLC’s holdings in Pfizer were worth $418,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of PFE. Worth Asset Management LLC bought a new position in Pfizer in the first quarter worth approximately $29,000. Rinkey Investments bought a new position in Pfizer in the fourth quarter worth approximately $32,000. Stuart Chaussee & Associates Inc. grew its stake in Pfizer by 108.3% in the first quarter. Stuart Chaussee & Associates Inc. now owns 625 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 325 shares in the last quarter. Advanced Research Investment Solutions LLC grew its stake in Pfizer by 339.3% in the first quarter. Advanced Research Investment Solutions LLC now owns 659 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 509 shares in the last quarter. Finally, Bivin & Associates Inc. purchased a new stake in Pfizer during the fourth quarter worth $37,000. Institutional investors own 67.90% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of analyst reports. UBS Group set a $59.00 target price on Pfizer in a report on Thursday, September 1st. SVB Leerink lowered their target price on Pfizer from $55.00 to $53.00 and set a “market perform” rating for the company in a report on Friday, July 29th. The Goldman Sachs Group set a $50.00 target price on Pfizer in a report on Thursday, September 1st. Berenberg Bank set a $44.00 target price on Pfizer in a report on Wednesday, September 14th. Finally, Barclays set a $50.00 target price on Pfizer in a report on Thursday, September 1st. Nine equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $57.00.

Pfizer Stock Performance

Shares of PFE stock opened at $44.57 on Friday. The firm has a market capitalization of $250.14 billion, a price-to-earnings ratio of 8.72, a price-to-earnings-growth ratio of 0.54 and a beta of 0.70. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.42 and a quick ratio of 1.20. The business has a fifty day moving average of $48.40 and a 200 day moving average of $50.33. Pfizer Inc. has a 1 year low of $40.94 and a 1 year high of $61.71.

Pfizer (NYSE:PFEGet Rating) last issued its earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.95 by $0.09. The company had revenue of $27.74 billion during the quarter, compared to analyst estimates of $26.20 billion. Pfizer had a return on equity of 43.18% and a net margin of 28.92%. The firm’s quarterly revenue was up 46.8% on a year-over-year basis. During the same quarter last year, the business posted $1.07 EPS. As a group, research analysts expect that Pfizer Inc. will post 6.54 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 5th. Shareholders of record on Friday, November 4th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 3.59%. Pfizer’s dividend payout ratio is currently 31.31%.

About Pfizer

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Read More

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.